Menu Search
Equities

Sino Biopharmaceutical Ltd

SMZ1:BER

Sino Biopharmaceutical Ltd

Actions
  • Price (EUR)0.4061
  • Today's Change-0.006 / -1.38%
  • Shares traded1.00k
  • 1 Year change-3.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Sino Biopharmaceutical Ltd's net income fell -8.32% from 2.54bn to 2.33bn despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 17.24% to 19.05%.
Gross margin82.92%
Net profit margin18.33%
Operating margin24.42%
Return on assets7.42%
Return on equity6.36%
Return on investment14.50%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Sino Biopharmaceutical Ltd fell by 1.15bn. However, the company earned 6.07bn from its operations for a Cash Flow Margin of 23.15%. In addition the company used 756.98m on investing activities and also paid 6.55bn in financing cash flows.
Cash flow per share0.3413
Price/Cash flow per share10.30
Book value per share1.95
Tangible book value per share1.76
More ▼

Balance sheet in CNYView more

Sino Biopharmaceutical Ltd has a Debt to Total Capital ratio of 18.68%, a higher figure than the previous year's 3.44%.
Current ratio1.15
Quick ratio1.07
Total debt/total equity0.2946
Total debt/total capital0.1868
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)1.33%
Div growth rate (5 year)1.15%
Payout ratio (TTM)50.02%
EPS growth(5 years)-27.21
EPS (TTM) vs
TTM 1 year ago		71.27
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.